Investment Analysts’ Weekly Ratings Changes for BridgeBio Pharma (BBIO)

A number of research firms have changed their ratings and price targets for BridgeBio Pharma (NASDAQ: BBIO):

• 10/21/2026 – BridgeBio Pharma had its price target lowered by Morgan Stanley from $97.00 to $87.00. They now have an “overweight” rating on the stock.
• 10/19/2026 – BridgeBio Pharma had its price target raised by Piper Sandler from $115.00 to $120.00. They now have an “overweight” rating on the stock.
• 10/19/2026 – BridgeBio Pharma had its price target lowered by Citigroup from $94.00 to $91.00. They now have a “neutral” rating on the stock.
• 10/15/2026 – BridgeBio Pharma had its “buy” rating reaffirmed by UBS Group. They now have a $92.00 price target on the stock, up from $82.00.
• 10/14/2026 – BridgeBio Pharma was upgraded by UBS Group to “strong-buy”.
• 10/7/2026 – BridgeBio Pharma had its price target lowered by Barclays from $157.00 to $156.00. They now have an “overweight” rating on the stock.
• 10/6/2026 – BridgeBio Pharma had its “buy” rating reaffirmed by HC Wainwright.
• 10/5/2026 – BridgeBio Pharma had its “buy” rating reaffirmed by Jefferies Financial Group.
• 10/5/2026 – BridgeBio Pharma had its “buy” rating reaffirmed by TD Cowen.
• 10/5/2026 – BridgeBio Pharma had its “overweight” rating reaffirmed by Cantor Fitzgerald.
• 9/25/2026 – BridgeBio Pharma was downgraded by Weiss Ratings from “sell (d)” to “sell (d-)”.
• 9/10/2026 – BridgeBio Pharma was upgraded by Weiss Ratings from “sell (d-)” to “sell (d)”.
• 9/10/2026 – BridgeBio Pharma had its “buy” rating reaffirmed by HC Wainwright. They now have a $120.00 price target on the stock.
• 9/2/2026 – BridgeBio Pharma had its “buy” rating reaffirmed by UBS Group.
• 9/2/2026 – BridgeBio Pharma had its “buy” rating reaffirmed by HC Wainwright. They now have a $120.00 price target on the stock.
• 9/1/2026 – BridgeBio Pharma had its price target raised by Mizuho from $96.00 to $110.00. They now have an “outperform” rating on the stock.

Insider Transactions at BridgeBio Pharma

In other news, CAO Maricel Apuli sold 2,000 shares of the business’s stock in a transaction on Thursday, July 30th. The shares were sold at an average price of $80.06, for a total transaction of $160,120.00. Following the completion of the sale, the chief accounting officer directly owned 127,401 shares of the company’s stock, valued at $10,199,724.06. The trade was a 1.55% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Neil Kumar sold 34,980 shares of the company’s stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $82.53, for a total value of $2,886,899.40. Following the sale, the chief executive officer owned 243,327 shares of the company’s stock, valued at approximately $20,081,777.31. The trade was a 12.57% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 56,980 shares of company stock valued at $4,578,119. Corporate insiders own 14.23% of the company’s stock.

BridgeBio Pharma, Inc is a biopharmaceutical company focused on discovering, developing and commercializing medicines for genetically driven diseases. The company operates through a portfolio of subsidiary and affiliated biotechnology businesses, with research programs spanning rare diseases, oncology, cardiology and other conditions linked to underlying genetic or molecular causes.

BridgeBio’s portfolio includes therapies designed to address the root mechanisms of disease rather than primarily treating symptoms.